AAAAAA

   
Results: 1-25 | 26-45
Results: 1-25/45
THE ASSOCIATION OF GEMCITABINE AND HEMOLYTIC-UREMIC SYNDROME - A CASE-REPORT
Authors: BERK SH SCHILSKY RL
Citation: Sh. Berk et Rl. Schilsky, THE ASSOCIATION OF GEMCITABINE AND HEMOLYTIC-UREMIC SYNDROME - A CASE-REPORT, Journal of investigative medicine, 46(7), 1998, pp. 274-274
PHASE-II AND PHARMACODYNAMIC STUDIES OF PYRAZINE DIAZOHYDROXIDE (NSC-361456) IN PATIENTS WITH ADVANCED RENAL AND COLORECTAL-CANCER
Authors: VOGELZANG NJ MANI S SCHILSKY RL ANSARI RH TABER D RHINEHART SN GARCIA JC MEYER SC MICK R BROCKSTEIN BE STADLER WM RATAIN MJ VOKES EE
Citation: Nj. Vogelzang et al., PHASE-II AND PHARMACODYNAMIC STUDIES OF PYRAZINE DIAZOHYDROXIDE (NSC-361456) IN PATIENTS WITH ADVANCED RENAL AND COLORECTAL-CANCER, Clinical cancer research, 4(4), 1998, pp. 929-934
PHASE-II AND PHARMACODYNAMIC STUDIES OF PYRAZINE DIAZOHYDROXIDE (NSC-361456) IN PATIENTS WITH ADVANCED RENAL AND COLORECTAL-CANCER
Authors: VOGELZANG NJ MANI S SCHILSKY RL ANSARI RH TABER D RHINEHART SN GARCIA JC MEYER SC MICK R BROCKSTEIN BE STADLER WM RATAIN MJ VOKES EE
Citation: Nj. Vogelzang et al., PHASE-II AND PHARMACODYNAMIC STUDIES OF PYRAZINE DIAZOHYDROXIDE (NSC-361456) IN PATIENTS WITH ADVANCED RENAL AND COLORECTAL-CANCER, Clinical cancer research, 4(4), 1998, pp. 929-934
PHASE-II TRIAL OF URACIL TEGAFUR (UFT) PLUS LEUCOVORIN IN PATIENTS WITH ADVANCED PANCREATIC-CARCINOMA - A UNIVERSITY-OF-CHICAGO PHASE-II CONSORTIUM STUDY/
Authors: MANI S KUGLER JW SCIORTINO DF GARCIA JC ANSARI RH HUMERICKHOUSE R MICHELASSI F POSNER MC SHULMAN KL SCHILSKY RL LIST M VOKES EE BENNER S
Citation: S. Mani et al., PHASE-II TRIAL OF URACIL TEGAFUR (UFT) PLUS LEUCOVORIN IN PATIENTS WITH ADVANCED PANCREATIC-CARCINOMA - A UNIVERSITY-OF-CHICAGO PHASE-II CONSORTIUM STUDY/, Annals of oncology, 9(9), 1998, pp. 1035-1037
POPULATION PHARMACOKINETIC DETERMINATION OF THE EFFECT OF FOOD ON THEPHARMACOKINETICS OF ORAL 5-FLUOROURACIL (FU) AND ENILURACIL (776C85, 776)
Authors: SHEPARD DR MANI S JANISCH L FLEMING GF SCHILSKY RL RATAIN MJ
Citation: Dr. Shepard et al., POPULATION PHARMACOKINETIC DETERMINATION OF THE EFFECT OF FOOD ON THEPHARMACOKINETICS OF ORAL 5-FLUOROURACIL (FU) AND ENILURACIL (776C85, 776), Annals of oncology, 9, 1998, pp. 600-600
PHASE-I STUDY OF ZD9331 USING A 5-DAY SHORT INFUSION SCHEDULE
Authors: RATAIN MJ GOH BC SMITH R BERTUCCI D MANI S VOGELZANG NJ SCHILSKY RL HUTCHISON M DOUGLASS E
Citation: Mj. Ratain et al., PHASE-I STUDY OF ZD9331 USING A 5-DAY SHORT INFUSION SCHEDULE, Annals of oncology, 9, 1998, pp. 616-616
A PHASE-I TRIAL OF CONTINUOUS-INFUSION 5-FLUOROURACIL AND WEEKLY GEMCITABINE - UPDATED RESULTS OF AN ACTIVE COMBINATION FOR RENAL-CELL, HEPATOCELLULAR AND COLON-CARCINOMA
Authors: MANI S GORDON G VOGELZANG NJ BERTUCCI D SCHILSKY RL STADLER WM RATAIN MJ
Citation: S. Mani et al., A PHASE-I TRIAL OF CONTINUOUS-INFUSION 5-FLUOROURACIL AND WEEKLY GEMCITABINE - UPDATED RESULTS OF AN ACTIVE COMBINATION FOR RENAL-CELL, HEPATOCELLULAR AND COLON-CARCINOMA, Annals of oncology, 9, 1998, pp. 632-632
RECENT ADVANCES IN ORAL FLUOROPYRIMIDINE THERAPIES
Authors: SCHILSKY RL
Citation: Rl. Schilsky, RECENT ADVANCES IN ORAL FLUOROPYRIMIDINE THERAPIES, Oncology, 12(10), 1998, pp. 9-11
BIOCHEMICAL AND CLINICAL-PHARMACOLOGY OF 5-FLUOROURACIL
Authors: SCHILSKY RL
Citation: Rl. Schilsky, BIOCHEMICAL AND CLINICAL-PHARMACOLOGY OF 5-FLUOROURACIL, Oncology, 12(10), 1998, pp. 13-18
O-6-BENZYLGUANINE IN HUMANS - METABOLIC, PHARMACOKINETIC, AND PHARMACODYNAMIC FINDINGS
Authors: DOLAN ME ROY SK FASANMADE AA PARAS PR SCHILSKY RL RATAIN MJ
Citation: Me. Dolan et al., O-6-BENZYLGUANINE IN HUMANS - METABOLIC, PHARMACOKINETIC, AND PHARMACODYNAMIC FINDINGS, Journal of clinical oncology, 16(5), 1998, pp. 1803-1810
PHASE-I AND PHARMACOKINETIC TRIAL OF PACLITAXEL IN PATIENTS WITH HEPATIC-DYSFUNCTION - CANCER AND LEUKEMIA GROUP-B-9264
Authors: VENOOK AP EGORIN MJ ROSNER GL BROWN TD JAHAN TM BATIST G HOHL R BUDMAN D RATAIN MJ KEARNS CM SCHILSKY RL
Citation: Ap. Venook et al., PHASE-I AND PHARMACOKINETIC TRIAL OF PACLITAXEL IN PATIENTS WITH HEPATIC-DYSFUNCTION - CANCER AND LEUKEMIA GROUP-B-9264, Journal of clinical oncology, 16(5), 1998, pp. 1811-1819
PHASE-I CLINICAL AND PHARMACOLOGICAL STUDY OF ENILURACIL PLUS FLUOROURACIL IN PATIENTS WITH ADVANCED CANCER
Authors: SCHILSKY RL HOHNEKER J RATAIN MJ JANISCH L SMETZER L LUCAS VS KHOR SP DIASIO R VONHOFF DD BURRIS HA
Citation: Rl. Schilsky et al., PHASE-I CLINICAL AND PHARMACOLOGICAL STUDY OF ENILURACIL PLUS FLUOROURACIL IN PATIENTS WITH ADVANCED CANCER, Journal of clinical oncology, 16(4), 1998, pp. 1450-1457
PHASE-I AND PHARMACOLOGICAL STUDY OF CONTINUOUS-INFUSION TOPOTECAN INCOMBINATION WITH CISPLATIN IN PATIENTS WITH ADVANCED CANCER - A CANCER AND LEUKEMIA GROUP-B STUDY
Authors: LILENBAUM RC MILLER AA BATIST G BERNARD S HOLLIS DR ROSNER GL EGORIN MJ SCHILSKY RL RATAIN MJ
Citation: Rc. Lilenbaum et al., PHASE-I AND PHARMACOLOGICAL STUDY OF CONTINUOUS-INFUSION TOPOTECAN INCOMBINATION WITH CISPLATIN IN PATIENTS WITH ADVANCED CANCER - A CANCER AND LEUKEMIA GROUP-B STUDY, Journal of clinical oncology, 16(10), 1998, pp. 3302-3309
MOPP ABV HYBRID CHEMOTHERAPY FOR ADVANCED HODGKINS-DISEASE SIGNIFICANTLY IMPROVES FAILURE-FREE AND OVERALL SURVIVAL - THE 8-YEAR RESULTS OFTHE INTERGROUP TRIAL/
Authors: GLICK JH YOUNG ML HARRINGTON D SCHILSKY RL BECK T NEIMAN R FISHER RI PETERSON BA OKEN MM
Citation: Jh. Glick et al., MOPP ABV HYBRID CHEMOTHERAPY FOR ADVANCED HODGKINS-DISEASE SIGNIFICANTLY IMPROVES FAILURE-FREE AND OVERALL SURVIVAL - THE 8-YEAR RESULTS OFTHE INTERGROUP TRIAL/, Journal of clinical oncology, 16(1), 1998, pp. 19-26
PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF ORAL 9-AMINOCAMPTOTHECIN (NSC-603071)
Authors: MANI S IYER L JANISCH L WANG XL FLEMING GF SCHILSKY RL RATAIN MJ
Citation: S. Mani et al., PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF ORAL 9-AMINOCAMPTOTHECIN (NSC-603071), Cancer chemotherapy and pharmacology, 42(1), 1998, pp. 84-87
ADJUVANT THERAPY FOR COLORECTAL-CANCER (REPRINTED FROM CURR PROBL SURG, VOL 34, PG 601-676, 1997)
Authors: COHEN AM MINSKY BD NELSON H GUNDERSON LL MICHELASSI F SALTZ L KELSEN DP WILLETT CG ARENAS RB FAROUK R SCHILSKY RL
Citation: Am. Cohen et al., ADJUVANT THERAPY FOR COLORECTAL-CANCER (REPRINTED FROM CURR PROBL SURG, VOL 34, PG 601-676, 1997), Current problems in cancer, 22(1), 1998, pp. 5-77
PHARMACOLOGY OF 21-DAY ORAL ETOPOSIDE GIVEN IN COMBINATION WITH IV CISPLATIN IN PATIENTS WITH EXTENSIVE-STAGE SMALL-CELL LUNG-CANCER - A CANCER AND LEUKEMIA GROUP-B STUDY (CALGB-9062)
Authors: MILLER AA ROSNER GL RATAIN MJ HOLLIS DR GREEN MR SCHILSKY RL
Citation: Aa. Miller et al., PHARMACOLOGY OF 21-DAY ORAL ETOPOSIDE GIVEN IN COMBINATION WITH IV CISPLATIN IN PATIENTS WITH EXTENSIVE-STAGE SMALL-CELL LUNG-CANCER - A CANCER AND LEUKEMIA GROUP-B STUDY (CALGB-9062), Clinical cancer research, 3(5), 1997, pp. 719-725
MODULATION OF VINBLASTINE RESISTANCE IN METASTATIC RENAL-CELL CARCINOMA WITH CYCLOSPORINE-A OR TAMOXIFEN - A CANCER AND LEUKEMIA GROUP-B STUDY
Authors: SAMUELS BL HOLLIS DR ROSNER GL TRUMP DL SHAPIRO CL VOGELZANG NJ SCHILSKY RL
Citation: Bl. Samuels et al., MODULATION OF VINBLASTINE RESISTANCE IN METASTATIC RENAL-CELL CARCINOMA WITH CYCLOSPORINE-A OR TAMOXIFEN - A CANCER AND LEUKEMIA GROUP-B STUDY, Clinical cancer research, 3(11), 1997, pp. 1977-1984
CONCOMITANT 5-FU, HYDROXYUREA AND CISPLATIN WITH EXTERNAL-BEAM RADIATION-THERAPY FOR LOCALLY ADVANCED PANCREATIC-CANCER - A PHASE-II STUDY
Authors: CHEN LM HARAF D BRACHMAN DG VOKES EE SCHILSKY RL
Citation: Lm. Chen et al., CONCOMITANT 5-FU, HYDROXYUREA AND CISPLATIN WITH EXTERNAL-BEAM RADIATION-THERAPY FOR LOCALLY ADVANCED PANCREATIC-CANCER - A PHASE-II STUDY, Oncology Reports, 4(5), 1997, pp. 877-881
PHASE-I STUDY OF 3'-DEAMINO-3'-(2-METHOXY-4-MORPHOLINYL)DOXORUBICIN (FCE-23762, PNU-152243) ADMINISTERED ON A DAILY X3 SCHEDULE
Authors: RATAIN MJ SKOOG LA OBRIEN SM COOPER N SCHILSKY RL VOGELZANG NJ GERBER M NARANG PK NICOL SJ
Citation: Mj. Ratain et al., PHASE-I STUDY OF 3'-DEAMINO-3'-(2-METHOXY-4-MORPHOLINYL)DOXORUBICIN (FCE-23762, PNU-152243) ADMINISTERED ON A DAILY X3 SCHEDULE, Annals of oncology, 8(8), 1997, pp. 807-809
PHASE-I STUDY OF TREATMENT WITH ORAL 13-CIS-RETINOIC ACID, SUBCUTANEOUS INTERFERON ALFA-2A, CISPLATIN, AND 24-HOUR INFUSION 5-FLUOROURACIL LEUCOVORIN/
Authors: FLEMING GF OBRIEN SM HOFFMAN PC VOKES EE VOGELZANG NJ SCHILSKY RL WAGGONER SE RATAIN MJ
Citation: Gf. Fleming et al., PHASE-I STUDY OF TREATMENT WITH ORAL 13-CIS-RETINOIC ACID, SUBCUTANEOUS INTERFERON ALFA-2A, CISPLATIN, AND 24-HOUR INFUSION 5-FLUOROURACIL LEUCOVORIN/, Cancer chemotherapy and pharmacology, 39(3), 1997, pp. 227-232
METHOTREXATE - AN EFFECTIVE AGENT FOR TREATING CANCER AND BUILDING CAREERS - THE POLYGLUTAMATE ERA
Authors: SCHILSKY RL
Citation: Rl. Schilsky, METHOTREXATE - AN EFFECTIVE AGENT FOR TREATING CANCER AND BUILDING CAREERS - THE POLYGLUTAMATE ERA, Stem cells, 14(1), 1996, pp. 29-32
INDIVIDUALIZED DOSING OF AMONAFIDE BASED ON A PHARMACODYNAMIC MODEL INCORPORATING ACETYLATOR PHENOTYPE AND GENDER
Authors: RATAIN MJ MICK R JANISCH L BEREZIN F SCHILSKY RL VOGELZANG NJ KUT M
Citation: Mj. Ratain et al., INDIVIDUALIZED DOSING OF AMONAFIDE BASED ON A PHARMACODYNAMIC MODEL INCORPORATING ACETYLATOR PHENOTYPE AND GENDER, Pharmacogenetics, 6(1), 1996, pp. 93-101
A PHASE-II TRIAL OF GEMCITABINE IN PATIENTS WITH 5-FU-REFRACTORY PANCREAS CANCER
Authors: ROTHENBERG ML MOORE MJ CRIPPS MC ANDERSEN JS PORTENOY RK BURRIS HA GREEN MR TARASSOFF PG BROWN TD CASPER ES STORNIOLO AM VONHOFF DD ALBERTS DS WOLFF R KELSEN DP KOCHA W HALLER DG MODIANOREVAH M MOORE M OKEN MM SCHILSKY RL SHAH A
Citation: Ml. Rothenberg et al., A PHASE-II TRIAL OF GEMCITABINE IN PATIENTS WITH 5-FU-REFRACTORY PANCREAS CANCER, Annals of oncology, 7(4), 1996, pp. 347-353
RELATIONSHIP BETWEEN TOXICITY AND OBESITY IN WOMEN RECEIVING ADJUVANTCHEMOTHERAPY FOR BREAST-CANCER - RESULTS FROM CANCER AND LEUKEMIA GROUP-B STUDY-8541
Authors: ROSNER GL HARGIS JB HOLLIS DR BUDMAN DR WEISS RB HENDERSON IC SCHILSKY RL
Citation: Gl. Rosner et al., RELATIONSHIP BETWEEN TOXICITY AND OBESITY IN WOMEN RECEIVING ADJUVANTCHEMOTHERAPY FOR BREAST-CANCER - RESULTS FROM CANCER AND LEUKEMIA GROUP-B STUDY-8541, Journal of clinical oncology, 14(11), 1996, pp. 3000-3008
Risultati: 1-25 | 26-45